Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202951 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL26976882 | 0.97 | DNM1 (0.36) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL27839357 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TDP1DNM1MEN1KMT2A | |
| SCHEMBL239620 | 0.89 | ALDH1A1 (0.54) | ALDH1A1TDP1DNM1MEN1KMT2A | |
| SCHEMBL1547342 | 0.88 | — | — | |
| SCHEMBL19588980 | 0.88 | — | — | |
| SCHEMBL19187626 | 0.88 | — | — | |
| SCHEMBL995550 | 0.88 | — | — | |
| SCHEMBL28084079 | 0.87 | DNM1 (0.43) | ALDH1A1TDP1DNM1MEN1KMT2A | |
| SCHEMBL2216199 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TDP1DNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105237-A1 | CURABLE RESIN COMPOSITION | 株式会社スリーボンド | 2025-05-22 | — | — | WO | disclosed |
| US-11180765-B2 | Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety | THE ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3770382-A1 | ELECTRIC POWER GENERATING SYSTEM | Nagashima, Kazuhiko (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-20210005562-A1 | PACKAGE STRUCTURE AND METHOD OF FORMING THE SAME | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2021-01-07 | — | — | US | disclosed |
| US-10784220-B2 | Plurality of semiconductor devices encapsulated by a molding material attached to a redistribution layer | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2020-09-22 | — | — | US | disclosed |
| US-10774334-B2 | Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety | Arizona Broad of Regents on Behalf of Arizona State University (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2020-02-27 | — | — | US | disclosed |
| US-20190148443-A1 | VERTICAL MICROBOLOMETER CONTACT SYSTEMS AND METHODS | TELEDYNE FLIR, LLC | 2019-05-16 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7371746-B2 | 1,2,4-Thiadiazole compounds and pests controlling composition containing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-7208585-B2 | Protein purification | GENENCOR INTERNATIONAL, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1765798-A2 | 1,2,4- THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| WO-2005037805-A2 | 1,2,4-THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | WO | disclosed |
| CN-1245500-A | Novel naphthyridine derivatives | SUMITOMO PHARMA (JP) | 2000-02-23 | — | — | CN | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | ALDH1A1 2381/4885TDP1 1314/4885CA12 4726/4885 |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | CYP4F3, CYP4B1, CYP4X1 | ALDH1A1 248/4885TDP1 877/4885CA12 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.